Literature DB >> 24583339

Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats.

Renu Agarwal1, Anna V Krasilnikova2, Intan Safinaz Raja3, Puneet Agarwal4, Nafeeza Mohd Ismail5.   

Abstract

Angiotensin converting enzyme inhibitors (ACEIs) have been shown to lower intraocular pressure (IOP). Since, the ACEIs cause increased tissue prostaglandin levels, we hypothesized that the mechanisms of ACEI-induced IOP reduction have similarity with those of prostaglandin analogs. The present study investigated the involvement of matrix metalloproteinases (MMPs) and cytokine activity modulation as the underlying mechanisms of ACEI-induced ocular hypotension. The IOP lowering effect of single drop of enalaprilat dehydrate 1% was evaluated in rats pretreated with a broad spectrum MMP inhibitor or a cytokine inhibitor. Effect of angiotensin receptor blocker, losartan potassium 2%, was also studied to evaluate involvement of angiotensin II receptor type 1 (AT1) in IOP lowering effect of ACEI. Topical treatment with single drop of enalaprilat resulted in significant IOP reduction in treated eye with mean peak reduction 20.3% at 3h post-instillation. Treatment with losartan resulted in a peak IOP reduction of 13.3%, which was significantly lower than enalaprilat, indicating involvement of mechanisms in addition to AT1 blockade. Pretreatment with a broad spectrum MMP inhibitor or a cytokine inhibitor significantly attenuated the enalprilat-induced IOP reduction with mean peak IOP reduction of 11.2% and 13.6% respectively. The IOP-lowering effect of enalaprilat seems to be attributed to reduced angiotensin II type 1 receptor stimulation and modulation of MMP and cytokines activities.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiotensin II type 1 receptor blocker; Angiotensin converting enzyme inhibitor; Enalaprilat; Intraocular pressure; Matrix metalloproteinase; Tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2014        PMID: 24583339     DOI: 10.1016/j.ejphar.2014.02.021

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Transcriptome analysis reveals autophagy as regulator of TGFβ/Smad-induced fibrogenesis in trabecular meshwork cells.

Authors:  April Nettesheim; Myoung Sup Shim; Josh Hirt; Paloma B Liton
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379

2.  Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.

Authors:  Mervi Holappa; Heikki Vapaatalo; Anu Vaajanen
Journal:  Ann Med       Date:  2020-04-30       Impact factor: 4.709

3.  Neuropathy optic glaucomatosa induced by systemic hypertension through activation endothelin-1 signaling pathway in central retinal artery in rats.

Authors:  Seskoati Prayitnaningsih; Hidayat Sujuti; Maksum Effendi; Aulia Abdullah; Nanda Wahyu Anandita; Febriani Yohana; Nur Permatasari; Mohamad Aris Widodo
Journal:  Int J Ophthalmol       Date:  2016-11-18       Impact factor: 1.779

4.  Continuous intraocular pressure monitoring in patients with obstructive sleep apnea syndrome using a contact lens sensor.

Authors:  Elena Carnero; Jean Bragard; Elena Urrestarazu; Estefanía Rivas; Vicente Polo; José Manuel Larrosa; Vanesa Antón; Antonio Peláez; Javier Moreno-Montañés
Journal:  PLoS One       Date:  2020-03-03       Impact factor: 3.240

Review 5.  Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.

Authors:  Alexander Vaneev; Victoria Tikhomirova; Natalia Chesnokova; Ekaterina Popova; Olga Beznos; Olga Kost; Natalia Klyachko
Journal:  Int J Mol Sci       Date:  2021-11-16       Impact factor: 5.923

6.  Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma.

Authors:  Harry A Quigley; Ian F Pitha; Derek S Welsbie; Cathy Nguyen; Matthew R Steinhart; Thao D Nguyen; Mary Ellen Pease; Ericka N Oglesby; Cynthia A Berlinicke; Katherine L Mitchell; Jessica Kim; Joan J Jefferys; Elizabeth C Kimball
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.